Læknablaðið

Årgang

Læknablaðið - 15.01.1999, Side 11

Læknablaðið - 15.01.1999, Side 11
LÆKNABLAÐIÐ 1999; 85 9 Meðferö viö lokastigsnýrnabilun á íslandi 1968-1997 Páll Ásmundsson, Runólfur Pálsson Ásmundssun P, Pálsson R Treatment of end-stage renal disease in Iceland 1968-1997 Læknablaðið 1999; 85: 9-24 Objective: Renal replacement therapy for end-stage renal disease (ESRD) has been provided in Iceland since 1968 when hemodialysis was begun. Kidney transplantation in Icelandic patients has been per- formed abroad since 1970 mainly in Copenhagen, Gothenburg and Boston. The purpose of this retro- spective study was to determine the changes in inci- dence, prevalence, and outcome of ESRD treatment during the period 1968-1997 and compare the results with other ESRD programs, mainly in the Nordic countries. Material and methods: Included in this study were all patients who began renal replacement therapy for ESRD during the study period and remained on therapy for at least six weeks. Data were obtained from the registry of ESRD, compiled by the Dialysis Service of the National University Hospital. The data were used to determine the annual incidence and prevalence of treated ESRD. Changes in parameters, such as age at the beginning of renal replacement therapy, gender distribution, causes of ESRD, treat- ment modalities, and survival were evaluated. An- nual mortality rate was calculated as deaths per 100 life-years. Comparison of means was done by the two sample t-test, survival was estimated by the Kap- lan-Meier method and survival differences were de- termined with the Mantel-Cox test. Results: A total of 201 patients began therapy for Frá blóöskilunardeild og lyflækningadeild Landspítalans. Fyrirspurnir, bréfaskipti: Páll Ásmundsson, blóðskilunar- deild Landspítalans, 101 Reykjavík; sími 560 1280, bréf- sími: 560 1287, netfang: pallas@rsp.is Lykilorö: lokastigsnýrnabilun, skilunarmeöferð, nýrna- ígræösla. ESRD during this 30 year period. The number of patients beginning renal replacement therapy in each of the three consecutive decades was 27, 59 and 115, respectively, which corresponds to 12.8, 25.1 and 44 per million population per year. The mean age rose throughout the study period and was 54.8 in the final decade. The prevalence per million population was 72 in 1977, 182 in 1987 and 356 in 1997. Diabetic nephropathy was not observed as a cause of ESRD until the last decade when it accounted for 12% of new patients. Hemodialysis was the sole dialysis modality until 1985. Peritoneal dialysis has since provided approximately one third of the dialysis treatment. The number of renal transplants was 13, 30 and 58 for each decade, respectively. At the end of 1997 there were 59 functioning allografts and of these 45 were from living donors. Patients with a functio- ning allograft were 70% of all ESRD patients at the end of 1997. Allografts came predominantly frorn cadaveric donors during the first two decades but living donors were 65% in the final decade. The five year survival of transplanted patients (81%) was markedly superior to that of dialyzed patients (16%). The annual mortality rate declined for the whole period, during the last decade it was 10.7 per 100 life-years for all patients, 27.9 for hemodialysis patients, 15.3 for peritoneal dialysis patients and 2.1 for transplanted patients. Death was mainly from cardiovascular causes and infections. Conclusions: There has been marked increase in the incidence and prevalence of treated ESRD in Iceland during the last 30 years. However, the incidence is low compared to the other Nordic countries, mainly as a result of low incidence of ESRD due to glomer- ulonephritis and diabetic nephropathy. Nearly half the ESRD population has received a renal transplant. Only Norway has a higher prevalence of transplanted patients among the ESRD pool. The percentage of living donor grafts among the transplanted patients is the highest the authors are aware of. Five year patient survival and renal allograft survival in Iceland were comparable to other countries. Keywords: end-stage renal failure, renal replacement therapy, kidney transplantation.
Side 1
Side 2
Side 3
Side 4
Side 5
Side 6
Side 7
Side 8
Side 9
Side 10
Side 11
Side 12
Side 13
Side 14
Side 15
Side 16
Side 17
Side 18
Side 19
Side 20
Side 21
Side 22
Side 23
Side 24
Side 25
Side 26
Side 27
Side 28
Side 29
Side 30
Side 31
Side 32
Side 33
Side 34
Side 35
Side 36
Side 37
Side 38
Side 39
Side 40
Side 41
Side 42
Side 43
Side 44
Side 45
Side 46
Side 47
Side 48
Side 49
Side 50
Side 51
Side 52
Side 53
Side 54
Side 55
Side 56
Side 57
Side 58
Side 59
Side 60
Side 61
Side 62
Side 63
Side 64
Side 65
Side 66
Side 67
Side 68
Side 69
Side 70
Side 71
Side 72
Side 73
Side 74
Side 75
Side 76
Side 77
Side 78
Side 79
Side 80
Side 81
Side 82
Side 83
Side 84
Side 85
Side 86
Side 87
Side 88
Side 89
Side 90
Side 91
Side 92
Side 93
Side 94
Side 95
Side 96
Side 97
Side 98
Side 99
Side 100
Side 101
Side 102
Side 103
Side 104
Side 105
Side 106
Side 107
Side 108
Side 109
Side 110
Side 111
Side 112
Side 113
Side 114
Side 115
Side 116

x

Læknablaðið

Direkte link

Hvis du vil linke til denne avis/magasin, skal du bruge disse links:

Link til denne avis/magasin: Læknablaðið
https://timarit.is/publication/986

Link til dette eksemplar:

Link til denne side:

Link til denne artikel:

Venligst ikke link direkte til billeder eller PDfs på Timarit.is, da sådanne webadresser kan ændres uden advarsel. Brug venligst de angivne webadresser for at linke til sitet.